Richard Yeatman

Richard Yeatman is Co-Founder and Chief Operating Officer of IgniteData, with over 15 years of experience spanning biopharmaceutical research, healthcare data, and enterprise software. He has contributed to peer-reviewed research on real-world data in clinical trials and is an advocate for interoperable, vendor-agnostic approaches to improving the efficiency and scalability of clinical research.

Posts by Richard Yeatman

MedCity Influencers

New Technology is Revolutionizing Clinical Trial Data Management — Here’s How Research Hospitals Can Seize the Moment

Options abound for hospitals looking to capitalize on these new data transfer technologies, but so do potential pitfalls. For any hospital considering adopting these new solutions, here are some of the key questions and considerations that should be top of mind.

Closing the Quality-Affordability Gap in Workplace Mental Health

In an interview, Kyan Health Co-Founder and Chief Commercial Officer Konstantin Struck discussed how Kyan gives mid-market and enterprise employers access to premium workforce mental healthcare, at a price point that is affordable.

By Stephanie Baum

Automation Didn’t Dehumanize Care. Bad Systems Did.

We have the opportunity to design systems that give people greater capacity for the work where human presence matters most: listening, understanding, reassuring, deciding, and caring.

By Michael Blackman, MD, MBA Chief Medical Officer, Greenway Health®

MedCity Influencers

Why Pharma Companies Should Look To Social Media For Better Patient Insight

Healthcare decision-makers, especially at pharmaceutical companies, must prioritize patient input. Data collected from social media listening is a significant step in the right direction.

By Rohit Marwah

Richard Yeatman

Posts by Richard Yeatman

New Technology is Revolutionizing Clinical Trial Data Management — Here’s How Research Hospitals Can Seize the Moment

Asahi Kasei Acquisition Pays Off With FDA Approval for Novel Herpes Drug

Outro Raises $7M To Support Safe Deprescribing

Pediatric Innovation Isn’t a Small-Market Problem, It’s an Incentive Problem